Akebia Therapeutics is recalling 2,170 bottles of Auryxia (ferric citrate) 210 mg tablets because of deviations from Current Good Manufacturing Practice (CGMP) standards. This prescription medication is used to control phosphorus levels in adults with chronic kidney disease on dialysis. The recall affects 200-count bottles from lot number 9062 with an expiration date of February 2021 that were distributed nationwide. Consumers should contact their healthcare provider or pharmacist regarding the use of this medication.
The recall is due to manufacturing deviations that may affect the quality and safety of the drug. While no specific injuries have been reported, failing to meet manufacturing standards can lead to products that do not meet their required specifications for strength, quality, or purity.
Healthcare consultation and pharmacy refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.